about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

5 years ago
R&D

Gilead, Gala­pa­gos claim PhI­Ib/III win for fil­go­tinib in ul­cer­a­tive col­i­tis — which pales in com­par­i­son to ri­vals

5 years ago
R&D

George Church spin­off swal­lows a key man­u­fac­tur­ing part­ner as it preps CRISPR-edit­ed pig or­gans for an­i­mal test­ing

5 years ago
Deals

Flush with $165M IPO cash, Zen­tal­is en­tices Ty­bourne, Or­biMed to fund a $20M Chi­na joint ven­ture

5 years ago
Financing

Al­ly Bridge joins Bain in $120M bet that speed­ing up man­u­fac­tur­ing QC can hit big in post-pan­dem­ic world

5 years ago
Financing
Outsourcing

No­var­tis taps Iya Khalil, physi­cist co-founder of GNS Health­care, to lead AI In­no­va­tion Cen­ter

5 years ago
People
AI

Covid-19 roundup: Trump says he's been tak­ing hy­drox­y­chloro­quine for days; Mod­er­na rais­es $1.3B on the heels of ...

5 years ago
Coronavirus

SEC backs Sino­vac's case against ac­tivist in­vestor who tried to take over; Blue­bird pen­cils in $400M raise

5 years ago
News Briefing

Swe­den's Cal­lid­i­tas seeks $75M IPO haul to bring its oral steroid to pa­tients with an or­phan kid­ney dis­ease

5 years ago
Financing

Bob Langer-found­ed cell ther­a­py play­er loads up $65M to fund Roche-part­nered can­cer work while ex­pand­ing in­to ...

5 years ago
Financing
Cell/Gene Tx

Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed ...

6 years ago
Deals

Covid-19 roundup: Trump ad­min­is­tra­tion prep­ping ex­ec or­der to re­duce re­liance on for­eign man­u­fac­tur­ing of 'essen­tial ...

6 years ago
Coronavirus

Stan­ford, Park­er In­sti­tute sci­en­tists team up with two young en­gi­neers in $20M AI play with an im­munol­o­gy fo­cus

6 years ago
Financing
AI

Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to ...

6 years ago
R&D
Pharma

Boehringer In­gel­heim sharp­ens reti­nal strat­e­gy, scoop­ing up dry AMD drug from a Swiss team be­hind No­var­tis' Beovu

6 years ago
Deals

Covid-19 roundup: Paul Hud­son says US will have first dibs on Sanofi vac­cine; Gilead se­lects 5 gener­ic man­u­fac­tur­ing ...

6 years ago
Coronavirus

Chi­nese biotech aims $232M in IPO cash to push next-gen prostate can­cer drug; Im­munomedics rais­es near­ly a ...

6 years ago
News Briefing

Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

6 years ago
Deals

Ex-DARPA chief Regi­na Dugan, for­mer Il­lu­mi­na CEO Jay Flat­ley lead $300M Well­come Trust fund to tack­le glob­al health's ...

6 years ago
People

'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

6 years ago
R&D

Spun out of George Church's lab, this biotech up­start is map­ping the AAV uni­verse for No­var­tis, Sarep­ta to gaze

6 years ago
Startups
Deals

A new play­er en­ters the KRAS game with Fortress; Gilead picks up once-failed can­cer drug from Molo­gen's fire sale

6 years ago
News Briefing

Amid lab space scarci­ty, a life sci­ences com­plex to rise in South San Fran­cis­co hub

6 years ago
Deals
R&D

FDA is­n't lift­ing the clin­i­cal hold on Sol­id Bio's Duchenne MD gene ther­a­py just yet — but is there a sil­ver ...

6 years ago
Cell/Gene Tx
FDA+
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times